Positive Phase III Results Show Genentech's Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer

Core Viewpoint - Genentech, a member of the Roche Group, announced positive results from the Phase III evERA study for giredestrant in combination with everolimus for treating specific breast cancer patients [1] Group 1: Study Results - The Phase III evERA study evaluated giredestrant combined with everolimus in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [1] - The study focused on patients who had previously been treated with a CDK 4/6 inhibitor and endocrine therapy [1]